News
Atonco plays an active role in finding new collaborators who are highly experienced in their field of expertise and in establishing partnerships with various actors involved in the field of alphatherapy.
ATONCO ANNOUNCES THE APPOINTMENT OF SYLVAIN FANIER AS NEW PRESIDENT OF ATONCO
Atonco announced today that Sylvain Fanier, Msc. EMBA, will succeed Professor Jean-François Chatal as President.
TELIX PARTNERS WITH FRENCH COMPANY ATONCO TO FIGHT BLADDER CANCER
Australian biopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX) has signed an agreement with France’s ATONCO S.A.S to investigate the use of Molecularly Targeted Radiation (MTR) technology.]